Cipla Shares Surge 4% as Citi Forecasts Major Growth Catalysts

Cipla shares witnessed a significant rally on Monday, climbing as much as 4% to hit a high of Rs 1,409 on the BSE. This optimism follows a strategic move by international brokerage firm Citi, which has placed the pharmaceutical giant on a 90-day "Positive Catalyst Watch."

US Market Triggers and Product Pipeline

Citi has maintained a ‘Buy’ rating for Cipla with a target price of Rs 1,700, implying a potential upside of approximately 25.55%. The brokerage identifies several near-term drivers in the US market that could fuel this growth. Key among these is the anticipated approval of gFlovent from the company's Goa facility, which is expected to bolster US revenue.

Furthermore, the expected launch of gVentolin and the strong performance of Nintedanib—which has already captured nearly 50% of its market share in the US—are significant tailwinds. Citi also expects a revenue rebound in the US segment following a recent period of weakness. Additionally, a pending re-inspection of the Indore plant by the USFDA remains a crucial event; a favorable outcome would serve as a major positive catalyst for investors.

Robust Domestic Performance and Valuation Edge

While the US market offers growth triggers, Cipla’s domestic operations remain a pillar of strength. The brokerage noted that the India business continues to perform well, supported by a recovery in its respiratory portfolio. Currently, the India business contributes nearly two-thirds of Cipla's EBITDA.

From a valuation perspective, Citi argues that Cipla offers more attractive exposure to the Indian pharmaceutical market compared to its peers. For instance, Cipla's India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. The brokerage also noted that easing geopolitical tensions have helped reduce concerns regarding raw material costs and margin pressures.

The bullish outlook comes despite a challenging Q4 performance. Cipla reported a 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same quarter last year. Revenue from operations also saw a slight dip of 3% YoY to Rs 6,541 crore. The EBITDA margin also contracted from 22.8% to 15.2% during this period.

However, Citi believes that Cipla's earnings have likely bottomed out following the impact of gRevlimid. With the stock trading at 25x FY27E earnings and 21x FY28E earnings, the brokerage sees a favorable risk-reward profile driven by upcoming US catalysts and improving domestic trends.

Key Takeaways

  • Bullish Outlook: Citi has set a target price of Rs 1,700, citing a 90-day window for positive catalysts including USFDA approvals and new product launches.
  • Market Dominance: Cipla's Nintedanib has secured a 50% market share in the US, while its domestic respiratory portfolio continues to drive steady growth.
  • Attractive Valuation: Compared to domestic peers like Mankind, Cipla offers a more reasonable valuation relative to its India-focused EBITDA contributions.